AI Could Accelerate Drug Development, But Faces Bottlenecks -- Market Talk

Dow Jones

Mar 13

0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. "Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome," the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 13, 2026 05:43 ET (09:43 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619987601"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619987601\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619987601?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-13 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619987601","market":"nz","top_or_hot":-1,"title":"AI Could Accelerate Drug Development, But Faces Bottlenecks -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. \"Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome,\" the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2026 05:43 ET (09:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AI Could Accelerate Drug Development, But Faces Bottlenecks -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAI Could Accelerate Drug Development, But Faces Bottlenecks -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-13 17:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. \"Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome,\" the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 13, 2026 05:43 ET (09:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AAQC","symbol_name":"Accelerate Acquisition Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619987601","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619987601","pubTimestamp":1773394980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. \"Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome,\" the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AAQC":"Accelerate Acquisition Corp"},"translate_title":"人工智能可以加速药物开发，但面临瓶颈——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAQC":1.5},"content_text":"0940 GMT - AI could help pharmaceutical companies shorten their drug-development processes, but the complexity of human biology remains the ultimate bottleneck, UBS analysts say in a research note. AI is currently being deployed to make drugmakers' operations more efficient in areas like regulatory documentation and financial processes, as opposed to core drug discovery, the analysts say, citing comments from executives at a recent conference hosted by UBS. \"Management teams clearly stated that AI can help identify targets in early drug discovery, but that it is ultimately still limited in its ability to reliably design drugs that achieve a predicted clinical outcome,\" the analysts say. The Stoxx Europe 600 Health Care index is up 0.1%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 05:43 ET (09:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}